SWOT Analysis:
Strength: Ticagrelor has strong efficacy and safety profile for treatment of acute coronary syndrome. It has demonstrated significant reduction in risk of myocardial infarction, stroke or cardiovascular death.Weakness: Being a relatively new drug, its long term safety is not well established yet. It also has some side effects like bleeding risk which limits its usage.Opportunity:...
The ticagrelor market covers the drug ticagrelor which is an oral, reversible, P2Y12 platelet aggregation inhibitor. Ticagrelor helps to prevent platelets from clumping together and forming clots. It is mainly used for reducing thrombotic cardiovascular events such as heart attack or stroke in patients with acute coronary syndrome or history of myocardial infarction. Ticagrelor market provides...
Ticagrelor is an antiplatelet medication used to prevent blood clots and to treat conditions such as myocardial infarction and unstable angina. It has shown significantly better outcomes than clopidogrel and is usually preferred in patients who are undergoing percutaneous coronary intervention. Ticagrelor works by reversibly binding to the P2Y12 receptor on platelets and inhibiting adenosine...
The Ticagrelor Market is estimated to be valued at US$ 1285.83 Mn in 2023 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: Ticagrelor is an antiplatelet drug used to treat acute coronary syndromes, including heart attacks and unstable angina. It works by inhibiting platelet...
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Romaian